CAPELLA: Wk 52 Results With Long-acting SC Lenacapavir in Persons With Multidrug-Resistant HIV

February 13-16, 2022; Virtual
Lenacapavir in combination with an optimized background regimen associated with virologic suppression in 83% of patients, 1 injection site reaction leading to discontinuation.
Format: Microsoft PowerPoint (.ppt)
File Size: 174 KB
Released: February 17, 2022


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck & Co., Inc.
ViiV Healthcare

Related Content

Dr Rodrigo Burgos discusses managing ART for people with HIV who are heavily treatment experienced, from Clinical Care Options (CCO)

person default Rodrigo Burgos, PharmD, MPH Released: February 6, 2023

Dr. José Arribas discusses the use of proviral DNA resistance testing when switching therapy in people with HIV, from Clinical Care Options (CCO)

José R. Arribas, MD Released: February 6, 2023

Get expert updates on ART safety and tolerability from fall conferences, from Clinical Care Options (CCO)

Eric K. Farmer, PharmD, BCPS, AAHIVP Darcy Wooten, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 24, 2023 Expired: January 23, 2024

European pioneers discuss the latest data and guideline recommendations for implementing LA ART into practice, from Clinical Care Options (CCO)

Celia Jonsson-Oldenbuettel, MD, PhD
Program Director
person default Tom Stephane De Wit, MD, PhD Eric Florence, MD, PhD Mireia SantaCreu Guerrero, MSN person default Laurence Slama, MD, PhD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: January 20, 2023 Expired: January 19, 2024

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings